BIO’s Evergreening Project: CEO Greenwood Discusses Cost-Effectiveness And The “Inevitability” Of Follow-On Biologics
James Greenwood joined the Biotechnology Industry Organization as president and CEO in January 2005 after 12 years in Congress. His priorities early on were to prevent drug safety worries from slowing approvals and to ensure the quality of BIO as an advocacy organization. Editors from "The Pink Sheet" spoke with Greenwood earlier this year about the challenges and opportunities facing the biotechnology industry in 2006.
You may also be interested in...
FDA should evaluate the effectiveness of risk management plans, Office of Pharmacoepidemiology & Statistical Science Director Paul Seligman said
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.